Folestad Agnetha, Ålund Martin, Asteberg Susanne, Fowelin Jesper, Aurell Ylva, Göthlin Jan, Cassuto Jean
Department of Orthopaedics, CapioLundby Hospital, Göteborg, Sweden.
Department of Orthopaedics, Sahlgrenska University Hospital, Mölndal, Sweden.
J Foot Ankle Res. 2015 Aug 18;8:39. doi: 10.1186/s13047-015-0096-3. eCollection 2015.
Little is currently known of the pathophysiological mechanisms triggering Charcot arthropathy and regulating its recovery although foot trauma has been proposed as a major initiating factor by activation of proinflammatory cytokines leading to increased osteoclastogenic activity and progressive bone destruction. Several members of the IL-17 family of proinflammatory cytokines have been shown to play a key role in the pathogenesis of inflammatory conditions affecting bone and joints but none has previously been studied in Charcot foot patients. The aim of this study was to investigate the role of IL-17A, IL-17E and IL-17F in patients presenting with Charcot foot.
Twenty-six consecutive Charcot patients were monitored during 2 years by repeated foot radiographs, MRI and circulating levels of IL-17A, IL-17E and IL-17F. Analysis of cytokines was done by ultra-sensitive chemiluminescence technique and data were analyzed by one-way repeated measures ANOVA. Neuropathic diabetic patients (n = 20) and healthy subjects (n = 20) served as controls.
Plasma IL-17A and IL-17E in weight-bearing Charcot patients at diagnosis were at the level of diabetic controls, whereas IL-17F was significantly lower than diabetic controls. A significant increase in IL-17A and IL-17E reaching a peak 2-4 months after inclusion and start of offloading treatment in Charcot patients was followed by a gradual decrease to the level of diabetic controls at 2 years postinclusion. In contrast, IL-17F increased gradually from inclusion to a level not significantly different from diabetic controls after 2 years.
Charcot patients display a significant elevation of all three IL-17 cytokines during the follow-up period relative values at diagnosis and values in control patients supporting a role in the bone repair and remodeling activity during the recovery phase. The rapid increase of IL-17A and IL-17E shortly after initiating off-loading treatment could suggest this to be a response to immobilization and stabilization of the diseased foot.
尽管足部创伤被认为是引发夏科氏关节病的主要起始因素,通过激活促炎细胞因子导致破骨细胞活性增加和进行性骨质破坏,但目前对触发夏科氏关节病并调节其恢复的病理生理机制知之甚少。促炎细胞因子白细胞介素-17(IL-17)家族的几个成员已被证明在影响骨骼和关节的炎症性疾病发病机制中起关键作用,但此前尚未在夏科氏足患者中进行研究。本研究的目的是调查IL-17A、IL-17E和IL-17F在夏科氏足患者中的作用。
通过重复足部X线片、磁共振成像(MRI)以及IL-17A、IL-17E和IL-17F的循环水平,对26例连续的夏科氏病患者进行了为期2年的监测。采用超灵敏化学发光技术分析细胞因子,并通过单向重复测量方差分析对数据进行分析。将神经性糖尿病患者(n = 20)和健康受试者(n = 20)作为对照。
诊断时负重的夏科氏病患者血浆IL-17A和IL-17E水平与糖尿病对照组相当,而IL-17F显著低于糖尿病对照组。夏科氏病患者在纳入研究并开始减负治疗后2-4个月,IL-17A和IL-17E显著增加并达到峰值,随后逐渐下降至纳入后2年时糖尿病对照组的水平。相比之下,IL-17F从纳入时开始逐渐升高,2年后达到与糖尿病对照组无显著差异的水平。
与诊断时的相对值和对照患者的值相比,夏科氏病患者在随访期间所有三种IL-17细胞因子均显著升高,这支持了它们在恢复阶段的骨修复和重塑活动中的作用。开始减负治疗后不久IL-17A和IL-17E迅速增加,这可能表明这是对患病足部固定和稳定的一种反应。